Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of drugs for treatment of cancers, especially subcutaneous T-cell lymphoma. In this study, we demonstrated that MPT0E028, a novel N-hydroxyacrylamide-derived HDAC inhibitor, inhibited human colorectal cancer HCT116 cell growth in vitro and in vivo. The results of NCI-60 screening showed that MPT0E028 inhibited proliferation in both solid and hematological tumor cell lines at micromolar concentrations, and was especially potent in HCT116 cells. MPT0E028 had a stronger apoptotic activity and inhibited HDACs activity more potently than SAHA, the first therapeutic HDAC inhibitor proved by FDA. In vivo murine model, the growth of HCT116 tumor xenograft was delayed and inhibited after treatment with MPT0E028 in a dose-dependent manner. Based on in vivo study, MPT0E028 showed stronger anti-cancer efficacy than SAHA. No significant body weight difference or other adverse effects were observed in both MPT0E028-and SAHA-treated groups. Taken together, our results demonstrate that MPT0E028 has several properties and is potential as a promising anti-cancer therapeutic drug.
References
[1]
Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85–94.
[2]
Beumer J, Tawbi H (2010) Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5: 196–208.
[3]
Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5.
[4]
Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958–3969.
[5]
Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600–608.
[6]
Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9: 3254–3266.
[7]
Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145–153.
[8]
Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 22: 2159–2168.
[9]
Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, et al. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology 10: 395–398.
[10]
Jazirehi AR (2010) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21: 805–813.
[11]
Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone Deacetylase Inhibitors: From Bench to Clinic. Journal of Medicinal Chemistry 51: 1505–1529.
[12]
Venugopal B, Evans T (2011) Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18: 1658–1671.
[13]
Chang J-Y, Hsieh H-P, Chang C-Y, Hsu K-S, Chiang Y-F, et al. (2006) 7-Aroyl-aminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents. Journal of Medicinal Chemistry 49: 6656–6659.
[14]
Chang J-Y, Lai M-J, Chang Y-T, Lee H-Y, Cheng Y-C, et al. (2010) Synthesis and biological evaluation of 7-arylindoline-1-benzenesulfonamides as a novel class of potent anticancer agents. MedChemComm 1: 152.
[15]
Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, et al. (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 1054–1065.
[16]
Paull K, Hamel E, Maalspeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor sreen of the National Cancer Institute, in Cancer Chemotherapeutic Agents. In: Foye W, editor. Cancer chemotherapeutic agents. Washington, DC: American Chemical Society.
[17]
Khosravi-Far R, White E, Shankar S, Srivastava RK (2007) Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis Programmed Cell Death in Cancer Progression and Therapy. Springer Netherlands. 261–298.
[18]
Takai N, Narahara H (2007) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14: 2548–2553.
[19]
Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, et al. (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18: 769–774.
[20]
Wilson AJ, Byun DS, Popova N, Murray LB, L’Italien K, et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548–13558.
[21]
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455–463.
[22]
Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, et al. (2010) Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer 127: 1384–1392.
[23]
Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, et al. (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 39: 1500–1509.
[24]
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, et al. (2005) RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25: 8097–8107.
[25]
Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser K, et al. (2007) Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 31: 1391–1402.
